Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Insite Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$3,534,258

776 payments

Through program year 2025, Insite Clinical Research is reported as receiving $3,534,258 in research payments, across 776 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,379,693 162
2024 Research $1,115,825 385
2023 Research $763,431 46
2022 Research $67,926 28
2021 Research $38,884 35
2020 Research $69,476 39
2019 Research $99,022 81

Breakdown

Who paid Research payments · program years 2019–2025
  1. ITI, Inc. $1,297,219 447 payments
  2. E.R. Squibb & Sons, L.L.C. $959,698 10 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $450,020 13 payments
  4. Indivior Inc. $419,524 74 payments
  5. Neurocrine Biosciences, Inc. $159,799 113 payments
  6. Eisai Inc. $101,855 71 payments
  7. Boehringer Ingelheim International GmbH $55,631 21 payments
  8. Novartis Pharmaceuticals Corporation $50,384 2 payments
  9. Boehringer Ingelheim Pharma GmbH & Co.KG $26,670 6 payments
  10. Boehringer Ingelheim RCV GmbH & Co KG $11,805 17 payments
Studies the money was for Research payments · program years 2019–2025
  1. Iti-007-451 $1,285,559 445 payments
  2. A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder $846,486 1 payment
  3. PoCP study Phase Ib of NR2B modulation in MDD $405,156 29 payments
  4. A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (Rbp-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-Risk Opioid Use $376,691 54 payments
  5. A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $101,855 71 payments
  6. A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia $93,157 64 payments
  7. BI 425809 Pivotal efficacy study 1 $62,899 6 payments
  8. A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder $54,159 1 payment
  9. A Double-Blind, Placebo-Controlled, Randomized Dose-Ranging Trial to Investigate Efficacy and Safety of Intravenous Mij821 Infusion in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent $50,384 2 payments
  10. Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia $49,958 30 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record